Product Description
KRIBIOLISA™ Anti-Tocilizumab (ACTEMRA) ELISA | KBI2022 | KRISHGEN BioSystems
Enzyme Immunoassay for the quantitative determination of Anti-Tocilizumab in serum and plasma.
Anti-Tocilizumab ELISA for screening of antibodies to Tocilizumab in human serum and plasma.
Intended Use:
The KRIBIOLISA™ Anti-Tocilizumab ELISA is used as an analytical tool for quantitative determination of
antibodies to Tocilizumab in serum, plasma and cell culture supernatant.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Tocilizumab is pre-coated onto
microwells. Samples and standards are pipetted into microwells and antibodies to Tocilizumab present in
the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated
Tocilizumab is pipetted and incubated. After washing microwells in order to remove any non-specific binding,
the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the
amount of antibodies to Tocilizumab present in the sample. Color development is then stopped by addition of
stop solution. Absorbance is measured at 450 nm.